IFNG and neoplasm: The combination of VZV-vax with the HPV16 L1165-173 and the tumor-specific E744-62 peptide led to an increase in IFN-γ-producing CD4+ T cells against the VZV gE protein (Fig. 6C) and of L1-specific and E7-specific CD8+ T cells (Fig. 6D, E) measured by dextramer staining.